Work

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

Year: 2021

Type: letter

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.06.017

Authors: D.J. McGrail, P.G. Pilié, N.U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, M. Khasraw, A.B. Heimberger, N.T. Ueno, R. Ferrarotto, J.T. Chang, S.-Y. Lin

Institutions: The University of Texas MD Anderson Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, The Netherlands Cancer Institute, Oncode Institute, Duke University, Northwestern University, The University of Texas Health Science Center at Houston

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Merck, Roche, Susan G. Komen, Daiichi-Sankyo, National Institutes of Health, Merck Sharp and Dohme, National Cancer Institute

Awards: G5396351703, G5920583325, G9000191564

OpenAlex ID: W3174833004

Cites: 6

Cited by: 2

Related to: 10